Conclusion
toxicities
Although the triplet combination in this study was limited by toxicities, the rationale for combining encorafenib and cetuximab with a Wnt pathway inhibitor holds promise. Future clinical trials involving Wnt pathway inhibitors must mitigate the risk of bone-related toxicities by intensively monitoring bone homeostasis and including bone protective measurements in their clinical trial protocols and patient selection. While novel combination approaches beyond inhibition of BRAF and EGFR are warranted for patients with BRAF 